{
  "slug": "maca",
  "version": "1",
  "displayName": "Maca root (Lepidium meyenii)",
  "unit": "g",
  "doseKind": "compound",
  "ingredientGroups": [
    "Maca"
  ],
  "shelfComparable": true,
  "primaryFloorId": "aisd-women-3g",
  "trialFloors": [
    {
      "id": "aisd-women-3g",
      "label": "Antidepressant-induced sexual dysfunction, women",
      "presetLabel": "Women 3 g",
      "amount": 3,
      "frequency": "daily",
      "horizon": "12 weeks",
      "evidenceLevel": "limited",
      "palette": "feminine",
      "pmids": [
        "25954318"
      ],
      "n": 42,
      "note": "Placebo-controlled, 45 women on SSRIs or SNRIs randomised. Remission favoured maca but stayed low in absolute terms — 9.5% vs 4.8% by ASEX and 30% vs 20% by MGH-SFQ — and the benefit clustered in postmenopausal women. Women only; there is no male equivalent of this trial.",
      "effectDirection": "benefit",
      "funding": "not-stated"
    },
    {
      "id": "dose-finding-arms",
      "label": "Dose-finding pilot, 1.5 g arm failed",
      "presetLabel": "Dose-finding",
      "amount": 1.5,
      "amountMax": 3,
      "frequency": "daily",
      "evidenceLevel": "limited",
      "palette": "research",
      "pmids": [
        "18801111"
      ],
      "n": 16,
      "note": "Head-to-head 1.5 g/day vs 3.0 g/day in 20 remitted depressed outpatients, 17 of them women. Only the 3.0 g arm improved significantly on ASEX and MGH-SFQ; 1.5 g/day did not separate. Ten completers. This is the entry's evidence that the lower dose is below the floor, not above it.",
      "effectDirection": "null",
      "funding": "not-stated"
    },
    {
      "id": "men-subjective-2400mg",
      "label": "Men with mild ED, subjective wellbeing",
      "presetLabel": "Men 2.4 g",
      "amount": 2.4,
      "frequency": "daily",
      "horizon": "12 weeks",
      "evidenceLevel": "limited",
      "palette": "research",
      "pmids": [
        "19260845"
      ],
      "n": 50,
      "note": "The only randomised maca trial in men, and it was mild general ED rather than antidepressant-induced. Both arms improved; maca improved more, but IIEF-5 gained only 1.6 points vs 0.5 on placebo — far below the roughly 4-point threshold for a change men notice. The paper frames its own outcome as subjective wellbeing.",
      "effectDirection": "secondary-only",
      "funding": "not-stated"
    }
  ],
  "guideSlugs": [
    "supplements-for-ssri-induced-ed"
  ],
  "guideUrls": [
    "https://supplementbrief.com/supplements-for-ssri-induced-ed/"
  ],
  "shelf": {
    "registrySlug": "maca",
    "label": "Maca root (Lepidium meyenii)",
    "productCount": 1239,
    "medianPerServing": 0.3,
    "p25PerServing": 0.1,
    "p75PerServing": 0.6,
    "belowPrimaryFloorPct": 94,
    "abovePrimaryFloorPct": 4,
    "unit": "g",
    "generatedAt": "2026-09-27T19:07:29.098Z",
    "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
  },
  "updatedDate": "2026-08-18",
  "dosePageUrl": "https://supplementbrief.com/dose/maca/",
  "jsonUrl": "https://supplementbrief.com/data/v1/doses/maca.json",
  "htmlUrl": "https://supplementbrief.com/data/v1/doses/maca/"
}
